Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

Compare

4,039 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SRPT Analyst Ratings

Hold

5 Buy

11 Hold

4 Sell

Based on 20 analysts giving stock ratings to

Sarepta

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SRPT Stock 12 Month Forecast

Average Price Target

$20.41

▼(-8.31% Downside)

Based on 20 Wall Street analysts offering 12 month price targets for Sarepta Therapeutics in the last 3 months. The average price target is $20.41 with a high forecast of $45.00 and a low forecast of $5.00. The average price target represents a -8.31% change from the last price of $22.26.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","35":"$35","66":"$66","97":"$97","128":"$128"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.41</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,35,66,97,128],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.01,25.624615384615385,27.239230769230772,28.853846153846156,30.46846153846154,32.08307692307692,33.69769230769231,35.3123076923077,36.926923076923075,38.541538461538465,40.15615384615384,41.77076923076923,43.385384615384616,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.01,23.733076923076926,23.456153846153846,23.17923076923077,22.902307692307694,22.625384615384615,22.34846153846154,22.071538461538463,21.794615384615383,21.517692307692307,21.24076923076923,20.963846153846156,20.686923076923076,{"y":20.41,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.01,22.54769230769231,21.085384615384616,19.623076923076923,18.160769230769233,16.698461538461537,15.236153846153847,13.773846153846154,12.311538461538461,10.849230769230768,9.386923076923075,7.924615384615382,6.462307692307693,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":123.29,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.95,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.59,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.72,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.75,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.78,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.74,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 79, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 93, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 26</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.16,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 84, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 25</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19.32,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 46, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 14</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":24.01,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$45.00

Average Price Target$20.41

Lowest Price Target$5.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yanan Zhu

Wells Fargo

$45

Buy

102.16%

Upside

Reiterated

11/26/25

Sarepta Therapeutics (SRPT) Gets a Buy from Wells Fargo

Sami Corwin

William Blair

―

Hold

―

Reiterated

11/25/25

Sarepta Therapeutics: Hold Rating Amid ENDEAVOR Progress and Short-term ChallengesWe view the FDA approval to initiate ENDEAVOR Cohort 8 as a constructive step toward addressing safety concerns that have limited Elevidys access for nonambulatory patients. The addition of sirolimus into the immunosuppression regimen is aligned with expert recommendations and preliminary supportive data presented at the World Muscle Society (WMS) and could provide a viable pathway to restoring the expanded label if successful. Positive results could enable Sarepta to pursue label reinstatement as early as 2027. However, more broadly we continue to view the stock’s near-term upside potential as limited given that the recent failure of the ESSENCE trial could put at risk of losing marketing authorization and a lack of clarity into Elevidys revenue guidance for the coming quarters.

William Pickering

Bernstein

$18→$20

Hold

-10.15%

Downside

Reiterated

11/25/25

Sarepta price target raised to $20 from $18 at BernsteinSarepta price target raised to $20 from $18 at Bernstein

Yigal Nochomovitz

Citi

$18.91→$8

Sell

-64.06%

Downside

Reiterated

11/24/25

Sell Rating for Sarepta Therapeutics Due to Risks in ENDEAVOR Study and Expected Share Price Decline

Michael Ulz

Morgan Stanley

$20

Hold

-10.15%

Downside

Reiterated

11/24/25

Cautious Outlook on Sarepta Therapeutics Amid Early-Stage Trials and Financial CommitmentsWe view continued advancement of the DM1 trial as a positive, and interim data updates from the siRNA pipeline remain on track for 1Q26 (likely back half). 02:18 PM GMTM Update 2 M Inc (ARWR.O) We derive our PT from a Discounted Cash Flow (DCF) analysis that uses a discount rate of 10% and a terminal growth rate of 1%.

Mitchell Kapoor

H.C. Wainwright

Sell

-77.54%

Downside

Reiterated

11/17/25

New Sarepta label weakens commercial narrative, says H.C. WainwrightNew Sarepta label weakens commercial narrative, says H.C. Wainwright

Uy Ear

Mizuho Securities

$26

Buy

16.80%

Upside

Reiterated

11/16/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Tazeen Ahmad

Bank of America Securities

$18

Sell

-19.14%

Downside

Reiterated

11/14/25

Sell Rating for Sarepta Therapeutics Amid Label Changes and Market Challenges

Gena Wang

Barclays

$22→$20

Hold

-10.15%

Downside

Reiterated

11/05/25

Barclays Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT)

Ritu Baral

TD Cowen

$17

Hold

-23.63%

Downside

Reiterated

11/04/25

Mixed Financial Signals and Future Revenue Concerns Lead to Hold Rating for Sarepta Therapeutics

Gavin Clark-Gartner

Evercore ISI

$17→$13

Hold

-41.60%

Downside

Reiterated

11/04/25

Evercore ISI Sticks to Their Hold Rating for Sarepta Therapeutics (SRPT)

Gil Blum

Needham

―

Sell

―

Reiterated

11/04/25

Sell Rating for Sarepta Therapeutics Amid ESSENCE Study Disappointment and Reimbursement Concerns

Brian Skorney

Robert W. Baird

$21→$15

Hold

-32.61%

Downside

Reiterated

11/04/25

Sarepta price target lowered to $15 from $21 at BairdSarepta price target lowered to $15 from $21 at Baird

Brian Abrahams

RBC Capital

$16

Hold

-28.12%

Downside

Reiterated

11/03/25

RBC Capital Remains a Hold on Sarepta Therapeutics (SRPT)

Biren Amin

Piper Sandler

$15→$16

Hold

-28.12%

Downside

Reiterated

10/30/25

Piper Sandler Sticks to Their Hold Rating for Sarepta Therapeutics (SRPT)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yanan Zhu

Wells Fargo

$45

Buy

102.16%

Upside

Reiterated

11/26/25

Sarepta Therapeutics (SRPT) Gets a Buy from Wells Fargo

Sami Corwin

William Blair

―

Hold

―

Reiterated

11/25/25

William Pickering

Bernstein

$18→$20

Hold

-10.15%

Downside

Reiterated

11/25/25

Sarepta price target raised to $20 from $18 at BernsteinSarepta price target raised to $20 from $18 at Bernstein

Yigal Nochomovitz

Citi

$18.91→$8

Sell

-64.06%

Downside

Reiterated

11/24/25

Sell Rating for Sarepta Therapeutics Due to Risks in ENDEAVOR Study and Expected Share Price Decline

Michael Ulz

Morgan Stanley

$20

Hold

-10.15%

Downside

Reiterated

11/24/25

Mitchell Kapoor

H.C. Wainwright

Sell

-77.54%

Downside

Reiterated

11/17/25

New Sarepta label weakens commercial narrative, says H.C. WainwrightNew Sarepta label weakens commercial narrative, says H.C. Wainwright

Uy Ear

Mizuho Securities

$26

Buy

16.80%

Upside

Reiterated

11/16/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Tazeen Ahmad

Bank of America Securities

$18

Sell

-19.14%

Downside

Reiterated

11/14/25

Sell Rating for Sarepta Therapeutics Amid Label Changes and Market Challenges

Gena Wang

Barclays

$22→$20

Hold

-10.15%

Downside

Reiterated

11/05/25

Barclays Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT)

Ritu Baral

TD Cowen

$17

Hold

-23.63%

Downside

Reiterated

11/04/25

Mixed Financial Signals and Future Revenue Concerns Lead to Hold Rating for Sarepta Therapeutics

Gavin Clark-Gartner

Evercore ISI

$17→$13

Hold

-41.60%

Downside

Reiterated

11/04/25

Evercore ISI Sticks to Their Hold Rating for Sarepta Therapeutics (SRPT)

Gil Blum

Needham

―

Sell

―

Reiterated

11/04/25

Sell Rating for Sarepta Therapeutics Amid ESSENCE Study Disappointment and Reimbursement Concerns

Brian Skorney

Robert W. Baird

$21→$15

Hold

-32.61%

Downside

Reiterated

11/04/25

Sarepta price target lowered to $15 from $21 at BairdSarepta price target lowered to $15 from $21 at Baird

Brian Abrahams

RBC Capital

$16

Hold

-28.12%

Downside

Reiterated

11/03/25

RBC Capital Remains a Hold on Sarepta Therapeutics (SRPT)

Biren Amin

Piper Sandler

$15→$16

Hold

-28.12%

Downside

Reiterated

10/30/25

Piper Sandler Sticks to Their Hold Rating for Sarepta Therapeutics (SRPT)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sarepta Therapeutics

1 Month

xxx

Success Rate

24/38 ratings generated profit

Average Return

+7.19%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 63.16% of your transactions generating a profit, with an average return of +7.19% per trade.

3 Months

xxx

Success Rate

22/38 ratings generated profit

Average Return

+7.53%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.89% of your transactions generating a profit, with an average return of +7.53% per trade.

1 Year

Debjit ChattopadhyayGuggenheim

Success Rate

20/38 ratings generated profit

Average Return

+10.24%

reiterated a buy rating 3 months ago

Copying Debjit Chattopadhyay's trades and holding each position for 1 Year would result in 52.63% of your transactions generating a profit, with an average return of +10.24% per trade.

2 Years

xxx

Success Rate

17/38 ratings generated profit

Average Return

+8.29%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 44.74% of your transactions generating a profit, with an average return of +8.29% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SRPT Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

150

156

130

In the current month, SRPT has received 6 Buy Ratings, 38 Hold Ratings, and 11 Sell Ratings. SRPT average Analyst price target in the past 3 months is 20.41.

Each month's total comprises the sum of three months' worth of ratings.

SRPT Financial Forecast

SRPT Earnings Forecast

Next quarter’s earnings estimate for SRPT is -$1.35 with a range of -$3.39 to $1.41. The previous quarter’s EPS was -$1.80. SRPT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year SRPT has Performed in-line its overall industry.

SRPT Sales Forecast

Next quarter’s sales forecast for SRPT is $377.55M with a range of $336.25M to $531.64M. The previous quarter’s sales results were $399.36M. SRPT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year SRPT has Performed in-line its overall industry.

SRPT Stock Forecast FAQ

What is SRPT’s average 12-month price target, according to analysts?

Based on analyst ratings, Sarepta Therapeutics’s 12-month average price target is 20.41.

What is SRPT’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for SRPT, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SRPT a Buy, Sell or Hold?

Sarepta Therapeutics has a consensus rating of Hold which is based on 5 buy ratings, 11 hold ratings and 4 sell ratings.

What is Sarepta Therapeutics’s price target?

The average price target for Sarepta Therapeutics is 20.41. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $45.00 ,the lowest forecast is $5.00. The average price target represents -8.31% Decrease from the current price of $22.26.

What do analysts say about Sarepta Therapeutics?

Sarepta Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of SRPT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

SRPT Analyst Ratings

SRPT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Sarepta Therapeutics

SRPT Analyst Recommendation Trends

SRPT Financial Forecast

SRPT Earnings Forecast

SRPT Sales Forecast

SRPT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts